Cervical Cancer Testing and How to Conduct Risk-Based Management

Cervical Cancer Testing and How to Conduct Risk-Based Management

Cervical Cancer testing and how to conduct risk-based management

    What changed in the recent CCS guideline updates from the ASCCP and ACS? Stay up to date so you can better triage and treat your patients.

    Available credits: 0.25

    Time to complete: 15 minutes


    Valid until:

    Take Post-Test

    If you’ve already completed the activity.

    • Overview

      Find out more about the new cervical cancer screening (CCS) guidelines that were issued by the American Society for Colposcopy and Cervical Pathology (ASCCP) and American Cancer Society (ACS). We walk you through the updates and explain the overall importance of ensuring that women do not fall off their testing schedule, whether clinicians are using cytology, co-testing, or primary HPV testing. We also review triage methods, FDA-approved tests, and the role of extended genotyping. Discover how to improve risk stratification and risk-based patient management and what impact regular CCS can have on health outcomes. 

    • Disclosure of Conflicts of Interest

      In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.


      Anna-Barbara Moscicki, MD
      Professor of Pediatrics
      Chief, Adolescent and Young Adult Medicine
      Los Angeles, CA
      Consulting Fees:

      Lee Philip Shulman, MD, FACMG, FACOG
      The Anna Ross Lapham Professor in Obstetrics and Gynecology (Clinical Genetics)
      Feinberg School of Medicine
      Northwestern University
      Chicago, IL
      Consulting Fees: Biogix, Celula, CooperSurgical, Natera, Vermillion/Aspira
      Commercial Interest Speakers Bureau: Bayer, Lupin Pharmaceuticals, Inc., Myriad

      Reviewers/Content Planners/Authors:

      • Sean T. Barrett has nothing to disclose.
      • Sue Grossman has nothing to disclose.
      • Libby Lurwick has nothing to disclose.
      • Estelle Perera has nothing to disclose.
      • Robert Schneider, MSW, has nothing to disclose.
    • Learning Objectives

      After participating in this educational activity, participants should be better able to:

      • Describe the key recommendations from the 2019 ASCCP CCS Guidelines and 2020 ACS Guideline update regarding risk stratification
      • Formulate strategies that maximize the risk stratification obtained using extended genotyping within clinical practice
    • Target Audience

      This activity is designed to meet the educational needs of obstetrician-gynecologists, primary care physicians, nurse practitioners, certified nurse midwives, and physician assistants.

    • Accreditation and Credit Designation Statements

      Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

      Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    • Provider(s)/Educational Partner(s)

      Omnia Education is the leading provider of education for women’s health professionals. Our activities are recognized nationwide for providing credible, relevant, and practical information on issues impacting the female patient. Additionally, our unique focus has transformed the CME learning environment, and our ability to help learners recognize and overcome barriers to optimal performance and optimal patient outcomes has positioned us as a leader in women’s health education.

    • Commercial Support

      This activity is supported by an independent educational grant from BD Life Sciences.

    • Disclaimer

      The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Omnia Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

      Reproduction Prohibited

      Reproduction of this material is not permitted without written permission from the copyright owner.

    • System Requirements

      Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

    Facebook Comments


    We’re glad to see you’re enjoying Omnia Education…
    but how about a more personalized experience?

    Register for free